IXICO Posts Strong H1 Revenue Growth and Boosts Order Book with Strategic Capital Raise

IXICO’s H1 2026: 23% Revenue Growth, Fatter Margins, and a Heavier Order Book

IXICO has kicked off FY26 with momentum. Today’s half-year trading update points to faster top-line growth, improving gross margins, and a significantly larger order book – all in line with full-year expectations. The company also reminds investors of the £10 million capital raise announced on 31 March 2026 to power its Tech Bio strategy.

Here’s what stood out, why it matters, and what I’ll be watching next.

Key numbers from the trading update

Metric	H1 2026	H1 2025	Change
Revenue	£3.9 million	£3.2 million	+23%
Gross margin	53%	50%	+3 percentage points
Order book (signed, not yet delivered)	£18.1 million	£13.1 million	+38% year-on-year
Order book vs FY 2025 (30 Sep)	£18.1 million	£13.8 million	+31% vs FY 2025
EBITDA loss	£0.5 million	£0.7 million loss	Narrowed by £0.2 million
Period-end cash	£1.7 million	£5.0 million	Down £3.3 million
Capital raise (31 March 2026)	£10.0 million gross (£9.4 million net)	n/a	Strategic investment

Note: “Order book” is defined as signed client contracts not yet delivered. EBITDA is earnings before interest, tax, depreciation and amortisation – a proxy for underlying operating performance.

What’s driving the improvement

Revenue mix and execution are working

Management flags three growth engines for H1 2026: new contract wins, contract extensions, and a higher volume of biomarker analyses. That blend suggests IXICO is landing new logos, expanding existing relationships, and increasing throughput on its platform – a healthy combination for a contract research model.

Crucially, gross margin stepped up to 53% (from 50%). That typically points to better operational leverage – more work going through the platform without a matching rise in delivery cost – and possibly a tilt towards higher-value services.

Order book expansion boosts revenue visibility

The order book increased to £18.1 million, up 38% year-on-year and up 31% versus the 30 September reference point (stated as FY 2025: £13.8 million). Larger backlogs are important in services businesses like iCROs, because they lock in future workload and smooth revenue trajectories.

One small caveat: the RNS references a comparison to “30 September 2026 (FY 2025: £13.8m)”. That date looks inconsistent with a FY 2025 comparator and is likely a typographical slip, but IXICO has not clarified this within the text.

EBITDA loss narrows despite investment

IXICO expects an EBITDA loss of £0.5 million, improved from a £0.7 million loss. Management links the residual loss to the full-period impact of investments under its Innovate, Lead, Scale strategy – essentially spending now to support sustained revenue growth. The margin improvement alongside that spend is encouraging.

Strategic capital raise: what it enables

On 31 March 2026, IXICO announced a £10.0 million capital raise (£9.4 million after costs) to support its Tech Bio strategy. The goal is to partner its IXI platform more deeply into the wider infrastructure of CROs (contract research organisations), CTMS (clinical trial management systems) and, ultimately, clinical healthcare providers.

Why it matters:

• Distribution and embed: Deepening integrations with CROs and CTMS could position IXICO’s AI-driven imaging analytics closer to the point of trial orchestration, making the platform more “default” in study design and execution.
• Scale effects: More integrated workflows can drive higher analysis volumes and data consistency, underpinning both growth and margin leverage.
• Clinical adjacency: Longer term, relationships with healthcare providers can expand the addressable market beyond trials into clinical monitoring – a sizeable prize, albeit a longer runway.

Cash at 31 March 2026 was £1.7 million, so the raise materially strengthens the balance sheet to pursue this strategy. The RNS does not disclose cash burn, runway, or any change in cost base beyond the strategic investment commentary.

CEO tone: confident and focused on profitability

CEO Bram Goorden highlights continued revenue momentum, improved gross margin, and a materially larger order book, concluding that the EBITDA loss has reduced year-on-year and the company is progressing towards profitability. It is measured, but confident – as you’d hope when reporting double-digit growth and better unit economics.

Dates for the diary (and a small oddity)

• Interim results date: 19 May 2026.
• Live presentation: the RNS states 19 May 2025 at 16:30 BST. That appears inconsistent with the results date and is likely a typographical error. Questions can be submitted up to 09:00 BST on 18 May 2026, according to the RNS.

The company says a recording of the presentation will be made available on its website. The RNS does not provide further details on presenters beyond CEO Bram Goorden and CFO Grant Nash.

Why this update matters for investors

• Quality of growth: Revenue up 23% with gross margin up to 53% suggests the business is scaling efficiently, not just growing for growth’s sake.
• Forward visibility: A £18.1 million order book gives stronger line-of-sight to H2 and beyond. Conversion timing will still matter, but the backlog is clearly building.
• Strategic firepower: The £10 million raise equips IXICO to embed its platform more deeply in trial infrastructure – a route to stickier demand and potential upsell.

Balanced view: positives and watchouts

Positives

• Double-digit revenue growth with higher margins – a solid operational step-up.
• Order book up 38% year-on-year, supporting future revenue confidence.
• EBITDA loss narrowing despite investment – signs of operating leverage.
• Fresh capital committed to a coherent scale-out plan in Tech Bio.

Watchouts

• Cash at period end was £1.7 million before the raise – the new funds need to translate into faster revenue and sustained margin gains.
• Order-to-revenue conversion and timing are not disclosed – execution cadence will be key in H2.
• Date inconsistencies in the RNS (presentation year and the “30 September 2026” reference) should be clarified by the company.
• No disclosure on net profit, cash flow, or headcount – we’ll need the full interim report for a deeper dive.

My take

This is a tidy update. IXICO is growing faster, doing it more profitably at the gross margin line, and banking a bigger backlog. The strategic raise looks sensibly targeted at distribution and integration, which is exactly where iCRO platforms win – by being embedded, repeat-use, and hard to swap out.

The near-term proof points I want next: steady order intake, stable-to-rising gross margin, and clear commentary on how the new capital accelerates partner integrations. Nail those, and the path to EBITDA breakeven starts to look achievable. For now, the direction of travel is positive.